Glucose and Lipid Metabolism on Antipsychotic Medication

Summary

This project aims to a) evaluate the effects of selected antipsychotic medications on insulin action in skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue (whole-body lipolysis), b) evaluate the effects of selected antipsychotic medications on abdominal adipose tissue mass, total body fat and total fat-free mass, and c) explore the longitudinal effects of treatment with selected antipsychotics on glucose tolerance, lipid profiles, abdominal adipose tissue mass, total body fat and total fat-free mass. These hypotheses will be evaluated by measuring 1) whole-body glucose and lipid kinetics with the use of "gold-standard" stable isotope tracer methodology, 2) body composition using dual energy x-ray absorptiometry and magnetic resonance imaging, and 3) longitudinal changes in glucose tolerance and lipid profiles. The aims will be addressed in non-diabetic schizophrenia patients chronically treated with risperidone, olanzapine, clozapine, quetiapine, ziprasidone, or haloperidol, and untreated healthy controls. Re-evaluations will also be performed in patients who are randomized to switch from their current antipsychotic (from the above groups) to risperidone, olanzapine, quetiapine, or ziprasidone for 6 months. Relevant data is critically needed to target basic research, identify long-term cardiovascular consequences, and plan therapeutic interventions.

Conditions

• Schizophrenia
• Schizoaffective Disorder
• Type 2 Diabetes Mellitus
• Hyperglycemia

Interventions

DRUG

risperidone

randomized to 12 week trial of risperidone.

DRUG

olanzapine

randomized to 12 week trial of olanzapine.

DRUG

quetiapine

randomized to 12 week trial of quetiapine.

DRUG

ziprasidone

randomized to 12 week trial of ziprasidone.

Sponsors & Collaborators

• National Institute of Mental Health (NIMH)

  collaborator NIH

• Washington University School of Medicine

  lead OTHER

Principal Investigators

• John W Newcomer, MD · Washington Univerisity School of Medicine and Florida Atlantic University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2001-09-30

Primary Completion

2008-12-31

Completion

2008-12-31

Countries

• United States

Study Locations